Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7683 results

  1. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

  2. School-based interventions: physical and mental health and wellbeing promotion

    In development [GID-QS10070] Expected publication date: TBC

  3. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

  4. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

  5. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

  6. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

  7. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

  8. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

  9. Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease

    In development [GID-IPG10345] Expected publication date: 17 April 2025

  10. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

  11. Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

    In development [GID-HTE10039] Expected publication date: 12 May 2025

  12. Pulsed field ablation for atrial fibrillation

    In development [GID-IPG10267] Expected publication date: 09 July 2025

  13. Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478

    Awaiting development [GID-TA11606] Expected publication date: TBC

  14. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development [GID-TA11615] Expected publication date: TBC

  15. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC